kgaa - Search News

News

Merck KGaA to Buy US Drugmaker Springworks

Reuters on MSN · 4h

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer t

Bloomberg on MSN · 1d

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the country.

Yahoo Finance · 1d

Merck KGaA to buy biotech SpringWorks for $3.9B

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

2d

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

GEN - Genetic Engineering and Biotechnology News9h

Merck KGaA to Acquire SpringWorks for $3.9B, Expanding Rare Cancer Footprint

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Fierce Pharma1d

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results